Curelab Veterinary Launches in Animal Health Sector, Leveraging Technology Licensed from CureLab Oncology
January 22, 2021
CureLab Oncology Submits Patent for COVID Therapeutic Ahead of Phase I Clinical Trials
June 30, 2021CureLab Oncology adds Hong Kong to expanding scope of patent protection
This month, the list of countries in which CureLab Oncology has established patent protection got a bit longer; CureLab Oncology has now been granted patent registration in Hong Kong SAR. Many companies use a HK patent to build a solid business strategy for their operations in PRC.
This brings the total number of countries in which CureLab Oncology has patent protection to over 20 — you can see the complete list here.
“CureLab Oncology (and its sister company, CureLab Veterinary) is pursuing dual patent protection approaches for our oncology and anti-inflammatory IP. In addition, CureLab Oncology is pursuing trademark protection for our lead product, Elenagen™.
Like any promising biotech company, we view a comprehensive, global approach to IP protection as immensely important to our strategic business plan. One reason is that annual industrial biopharmaceutical R&D spending has declined over the past decade, with large pharmaceuticals instead focusing on partnership and acquisition strategies with biotech startups whose technology shows great promise.
As we expand our patent portfolio and geographic operations, we will adapt our IP strategy to maximize the value of the company.
